Daily Stock Analysis, EBS, Emergent BioSolutions Inc, priceseries

Emergent BioSolutions Inc. is a global specialty biopharmaceutical company focused on the development, manufacture and distribution of a portfolio of medical countermeasures (vaccines, therapeutics and other novel products) and related services for civilian and military populations that address intentional and naturally emerging public health threats, specifically Chemical, Biological, Radiological, Nuclear and Explosive, or CBRNE, threats as well as emerging infectious diseases. The company operations include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing and domestic government affairs in support of its portfolio of marketed products, as well as product development and manufacturing infrastructure in support of its portfolio of investigational stage product candidates. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.